Table 2.
Clinical and parasitological outcome of Plasmodium vivax affected patients treated with combined doses of CQ–PQ for 14 days (T14) or with an intermittent single dose (ISD)
| N Days (mean/SD) |
57e
(2/0) |
59e
(3/0.15) |
54 (7.2/0.74) |
54 (14.6/1.1) |
56 (21.4/1.2) |
60 (29.8/2.9) |
|---|---|---|---|---|---|---|
| Single dose | ||||||
| Clinical outcome (% with symptoms) | ||||||
| Fever | 10.17† | 3.70† | 1.8† | 0 | 0 | 0 |
| Headache | 30.51† | 16.67† | 3.7† | 5.3† | 3.3† | 0 |
| Mialgias | 1.69† | 3.39† | 0 | 0 | 0 | 0 |
| Arthralgias | 0 | 0 | 0 | 0 | 0 | 0 |
| Blisters | 5.08 | 6.78 | 7.41 | 3.7 | 1.8 | 0 |
| Erythema/pruritus | 10.17 | 8.47 | 1.85 | 0 | 0 | 0 |
| Light jaundice | 11.86 | 13.56* | 11.11* | 9.2* | 3.6 | 0 |
| Asexual parasitaemia by microscopy | ||||||
| Positivity: n, %a | 14, 23.7 | 3, 5.0 | 0 | 0 | 0 | 2, 3.4 |
| p/µlb: median (IQR)c | 62 (68) | 157.7 (59.1) | – | – | – | 223 (163) |
| % PCR positived | 41.3 | 12.7 | 0 | 0 | 0 | 3.4 |
| N Days (mean/SD) |
81 (2) |
75 (3) |
63 (7) |
49 (14) |
44 (21.5/1.1) |
44 (29/2.5) |
|---|---|---|---|---|---|---|
| 14-day (T14) | ||||||
| Clinical outcome (% with symptoms) | ||||||
| Fever | 2.67† | 3.17† | 0 | 0 | 0 | 0 |
| Headache | 25.33† | 7.94† | 0 | 2.2† | 0 | 0 |
| Mialgias | 2.47† | 4.0† | 0 | 0 | 0 | 0 |
| Arthralgias | 1.23 | 1.33 | 0 | 0 | 0 | 0 |
| Blisters | 3.70 | 4.0 | 3.17 | 0 | 0 | 0 |
| Erythema/pruritus | 7.41 | 9.33 | 6.35 | 4.1 | 0 | 0 |
| Light jaundice | 23.46 | 32.0* | 36.5* | 40.8* | 13.6 | 2.2 |
| Asexual parasitaemia by microscopy | ||||||
| Positivity: n, %a | 13, 16 | 4, 5.1 | 0 | 0 | 0 | 0 |
| p/µlb: median (IQR)c | 118 (180) | 42.4 (43.0) | – | – | – | – |
| % PCR positived | 34.1 | 8.75 | 0 | 0 | 0 | 0 |
N number of patients
* Statistical differences were detected on days 3 (p = 0.004), 7 (p = 0.007) and 14 (p = 0.002) in both treatment groups (Fisher exact test, α = 0.05)
† As indicated by the patients, this symptom was present between visits
an and %, number and percent of samples with asexual parasites
bNumber of asexual parasites per microlitre of blood
cOnly positive samples were included
dPercent of samples positive by molecular analysis
ePatients sampled on day 2 were not sampled on day 3 and vice versa